Alternative agents used in ADHD;Substanzgebundene alternativen in der therapie von ADHS

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 37, Issue 1, 2009, Pages 13-25

  Häßler, Frank ^a   Dück, Alexander ^a   Reis, Olaf ^a   Buchmann, Johannes ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

ADHD; Alternative drugs and substances; Childhood and adolescence

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CLONIDINE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LEVODOPA; MAGNESIUM; MELATONIN; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; POLYUNSATURATED FATTY ACID; PSYCHOTROPIC AGENT; PYCNOGENOL; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZINC; CENTRAL STIMULANT AGENT; NORADRENALIN; SEROTONIN;

ADOLESCENT; AGE DISTRIBUTION; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CLINICAL TRIAL; COMORBIDITY; COORDINATION DISORDER; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HOMEOPATHY; HUMAN; HYPERTENSION; HYPONATREMIA; INDUCED HYPOTENSION; INSOMNIA; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NAUSEA; NERVE CONDUCTION; PRESCHOOL CHILD; PREVALENCE; QUALITY OF LIFE; REVIEW; SCHOOL CHILD; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY; SUICIDAL IDEATION; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA; BRAIN; DRUG COMBINATION; DRUG SURVEILLANCE PROGRAM; METABOLISM; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DRUG THERAPY, COMBINATION; HUMANS; NOREPINEPHRINE; PSYCHOTROPIC DRUGS; SEROTONIN;

EID: 63249131336     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.37.1.13     Document Type: Review

References (82)

1. Abikoff, H., McGough, J., Vitiello, B., McCracken, J., Davis, M. & Walkup, J. (2005). Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 418-427. (Pubitemid 40559689)
2. Adler, L. A., Resnick, S., Kunz, M. & Devinsky, O. (1995). Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacological Bulletin, 31, 785-788.
3. Akhondzadeh, S., Mohammadi, M. R. & Khademi, M. (2004). Zinc sulfate as adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double-blind and randomized trial. BMC Psychiatry, 4, 9-14.
4. Aman, M. G., Mitchell, E. A. & Turbott, S. H. (1987). The effects of essential fatty acid supplementation by Efamol in hyperactive children. Journal of Abnormal Child Psychology, 15, 75-90. (Pubitemid 17039438)
5. Aman, M. G., De Smedt, G., Derivan, A. & Lyons, B., Risperidone disruptive behavior study group (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. American Journal of Psychiatry, 159, 1337-1346.
6. Antkowiak, R. & Rajewski, A. (1998). Administration of moclobemide ++ in children with attention deficit hyperactivity disorder. Psychiatria Polska, 32, 751-757.
7. Arnold, L. E., Bozzolo, H., Hollway, J., Cook, A., DiSilvestro, R. A., Bozzolo, D. R., Crowl, L., Ramadan, Y. & Williams, C. (2005). Serum zinc correlates with parent- and teacher - rated inattention in children with attention - deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 15, 628-636. (Pubitemid 41434367)
8. Barrickman, L., Perry, P., Allen, A., Kuperman, S., Arndt, S. V. & Herrmann, K. J. (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 649-657.
9. Bekaroglu, M., Yakup, A., Yusof , G., Orhan, D., Hilal, M., Erol, E. & Caner, K. (1996). Relationships between serum-free fatty acids and zinc and ADHD. Journal of Child Psychology and Psychiatry, 37, 225-227.
10. Biederman, J., Melmed, R. D., McBurnett, K., Konow, J., Lyne, A., Scherer, N. & fort he SPD503 Study Group (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121, 73e-e84.
11. Bilici, M., Yildirim, F., Kandil, S., Bekaroglu, M., Yildirmis, S., Deger, O., Ülgen, M., Yildiran, A. & Aksu, H. (2004). Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 181-190.
12. Buitelaar, J. K., Van der Gaag, R. J., Swaab-Barneveld, H. & Kuiper, M. (1996). Pindolol and methylphenidate in children with attention-deficit hyperactivity disorder. Clinical efficacy and side-effects. Journal of Child Psychology and Psychiatry, 37, 587-595. (Pubitemid 26196492)
13. Burgess, J. R., Stevens, L. J., Zhang, W. & Peck, L. (2000). Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition, 71, 327-330.
14. Cantwell, D. P., Swanson, J. & Connor, D. F. (1997). Case study: adverse response to clonidine. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 539-544. (Pubitemid 27149192)
15. Casat, C. D., Pleasants, D. Z. & Fleet, J. V. W. (1987). A double blind trial of bupropion in children with attention deficit disorder. Psychopharmacological Bulletin, 23, 120-122.
16. 1A receptor agonists and subtypes of alpha-1-adrenoreceptors on rabbit aorta. European Journal of Pharmacology, 24, 141-148.
17. Chen, J. R., Hsu, S. F., Hsu, C. D., Hwang, L. H. & Yang, S. C. (2004). Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. Journal of Nutritional Biochemistry, 15, 467-472. (Pubitemid 39118493)
18. Conners, C. K., Casat, C. D., Gualtieri, C. T., Weller, E., Reader, M. & Reiss, A. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child & Adolescent Psychiatry, 35, 1314-1321. (Pubitemid 26327705)
19. Connor, D. F. (1993). Beta blockers for aggression: A review of the pediatric experience. Journal of Child and Adolescent Psychopharmacology, 2, 99-114.
20. Connor, D. F., Fletcher, K. E. & Swanson, J. M. (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1551-1559.
21. Cosgrove, P. V. F. (1996). Risperidone added to methylphenidate in attention deficit hyperactivity disorder. European Neuropsychopharmacology, 6 (suppl. 3), 11-12.
22. Coulter, M. K. & Dean, M. E. (2007). Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. Cochrane database of systematic reviews 2007; 4: Art. No.: CD005648.DOI:10.1002/1451858.CD005648. pub2.
23. Croonenberghs, J., Fegert, J. M., Findling, R. L., De Smedt, G., Van Dongen, S. & the Risperidone Disruptive Behavior Study Group (2005). Risperidone in children with behavior disorders and subaverage intelligence: A 1-Year, open-label study of 504 patients. Journal of the American Academy of Child & Adolescent Psychiatry, 1, 64-72.
24. Döpfner, M. (2006). Alternative Therapien. ADHS-Report, 23, 1-4.
25. Döpfner, M., Lehmkuhl, G., Schepker, R. & Fröhlich, J. (2007). Hyperkinetische Störungen (F 90). In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Berufsverband der Ärzte für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (Hrsg.) Köln, Deutscher Ärzteverlag, 239-254.
26. Elia, J., Ambrosini, P. J. & Rapoport, J. L. (1999). Treatment of atttention-deficit-hyperactivity disorder. New England Journal of Medicine, 340, 780-788.
27. Engelberg, H. (1992). Low serum cholesterol and suicide. Lancet, 339, 727-729.
28. Findling, R. L., Schwartz, M. A., Flannery, D. J. & Manos, M. J. (1996). Venlafaxine in adults with attention deficit/hyperactivity disorder: an open clinical trial. Journal of Clinical Psychiatry, 57, 184-189. (Pubitemid 26158852)
29. Frei, H., Everts, R., von Ammon, K., Kaufmann, F., Walther, D., Hsu-Schmitz, S., Collenberg, M., Fuhrer, K., Hassink, R., Steinlein, M. & Thurneysen, A. (2005). Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised double blind, placebo controlled crossover trial. European Journal of Pediatrics, 164, 758-767. (Pubitemid 41609477)
30. Frei, H., Everts, R., von Ammon, K., Kaufmann, F., Walther, D., Schmitz, S. F., Collenberg, M., Steinlein, M., Lim, C. & Thurneysen, A. (2007). Randomised controlled trials of homeopathy in hyperactive children: treatment procedure leads to an unconventional study design. Experience with open-label homeopathic treatment preceding the Swiss ADHD placebo controlled, randomised, double-blind, cross-over trial. Homeopathy, 96, 35-41.
31. Gittelman-Klein, R., Klein, D. F. & Katz, S. (1976). Comparative effects of methylphenidate and thioridazine in hyperactive children: I. Clinical results. Archives of General Psychiatry, 33, 1217-1231.
32. Gross, M. D. (1995). Buspirone in ADHD with ODD (Letter). Journal of the American Academy of Child & Adolescent Psychiatry, 34, 1260.
33. Greenberg, L. M., Deem, M. A. & McMahon, S. (1972). Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. American Journal of Psychiatry, 129, 532-539.
34. Greydanus, D. (2005). Pharmacological treatment of attention-deficit hyperactivity disorder. Indian Journal of Psychiatry, 72, 953-960. (Pubitemid 41754496)
35. Häßler, F., Göhre, C. & Irmisch, G. (2003). Buspiron - eine Alternative zu Stimulanzien in der Therapie hyperkinetischer Störungen. In: Lehmkuhl, U. (Hrsg.): Psychotherapie und Psychopharmakotherapie im Kindes- und Jugendalter. Göttingen: Vandenhoeck & Ruprecht, 100-107.
36. Häßler, F., Buchmann, J. & Reis, O. (2005). Psychopharmaka und Polypharmazie. Nervenheilkunde, 24, 811-818.
37. Häßler, F., Dück, A., Reis, O. & Buchmann, J. (2007). «Alternative » pharmakologische Therapien bei ADHS. Psychopharmakotherapie, 14, 229-236.
38. Hazell, P. L., McDowell, M. & Walton, J. (1996). Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of New South Wales. Medical Journal of Australia, 165, 477-480. (Pubitemid 26379024)
39. Hazell, P. L. & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child & Adolescent Psychiatry, 42, 886-894. (Pubitemid 44515836)
40. Hedges, D., Reimherr, F. W., Rogers, A. & Strong, R. et al. (1995). An open trial of venlafaxin in adult patients with attention hyperactivity disorder. Psychopharmacological Bulletin, 31, 779-783.
41. Heijden van, K. B., Smits, M. G., Someren van, E. J. W., Ridderinkhof, K. R. & Gunning, W. B. (2007). Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 233-241. (Pubitemid 46148422)
42. Hibbeln, J. R., Linnoila, M., Umhau, J. C., Rawlings, R., George, D. T. & Salem, N. (1998). Essential Fatty Acids Predict Metabolites of Serotonin and Dopamine in Cerebrospinal Fluid among Healthy Control Subjects, and Early-and Late-Onset Alcoholics. Biological Psychiatry, 44, 235-242.
43. Himpel, S., Banaschewski, T., Heise, C.A. & Rothenberger, A. (2005). The safety of non-stimulant agents fort he treatment of attention-deficit hyperactivity disorder. Expert Opinion on Drug Safety, 4, 311-321.
44. Holtmann, M., Bölte, S., Wöckel, L. & Poustka, F. (2005). Antidepressive Therapie bei Kindern und Jugendlichen: Anwendung und Stellenwert der selektiven Serotonin-Wiederaufnahmehemmer. Deutsches Ärzteblatt, 226.
45. Irmisch, G., Wiechert, P., Häßler, F. & Langemann, I. (1992). Fatty acid patterns of serum lipids and the hypermotoric syndrome. Neurosciences, 18, 77-80.
46. Jacobs, J., Williams, A. L., Girard, C., Njike, V. Y. & Katz, D. (2005). Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized controlled trial. Journal of Alternative and Complementary Medicine, 11, 799-806. (Pubitemid 41739353)
47. Johnston, J. A., Ye ,W., Van Brunt, D. L., Pohl, G. & Sumner, C. R. (2006). Decreased use of clonidine following treatment with atomoxetine in children with ADHD. Journal of Clinical Psychopharmacology, 26, 389-395. (Pubitemid 44187641)
48. Joshi, K., Lad, S., Kale, M., Patwardhan, B., Mahadik, S. P., Patni, B., Chaudhary, A., Bhave, S. & Pandit, A. (2006). Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins, Leukotrienes and Essential Fatty Acids , 74, 17-21. (Pubitemid 41773064)
49. Langer, D. H., Rapoport, J. L., Brown, G. L., Ebert, M. H. & Bunney, W. E. (1982). Behavioral aspects of carbidopa/levodopa in hyperactive boys. Journal of the American Academy of Child & Adolescent Psychiatry, 21, 10-18.
50. Malhotra, S. & Santosh, P. J. (1998). An open clinical trial of buspirone in children with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 364-371. (Pubitemid 28162889)
51. Mann, J. J. (1995). Violence and aggression. In: Bloom, F.E., Kupfer, D.J. (eds) Psychopharmacology: The Fourth Generation of Progress. Raven, New York, 1919-1928.
52. Mattes, J. A. & Gittelman, R. (1979). A pilot trial of amantadine in hyperactive children. Paper presented at the NCDEU meeting. KEY Biscayne, Florida.
53. Mattes, J. A. (1986). Propranolol for adults with temper outbursts and residual attention deficit disorder. Journal of Clinical Psychopharmacologyogy, 6, 299-302. (Pubitemid 17206874)
54. Mitchell, E. A., Aman, M. G., Turbott, S. H. & Manku, M. (1987). Clinical characteristics and serum essential fatty acids levels in hyperactive children. Clinical Pediatrics, 26, 406-411.
55. Mousin-Bosc, M., Roche, M., Rapin, J. & Bali, J. P. (2004). Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. Journal of the American College of Nutrition, 23, 545-548.
56. Overtoon, C. C., Verbaten, M. N., Kemner, C., Kenemans, J. L., van Engeland, H., Buitelaar, J. K., van der Molen, M. W., van der Gugten, J., Westenberg, H., Maes, R. A. & Koelega, H. S. (2003). Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behavioral Brain Research, 145, 7-15.
57. Palumbo, D. R., Sallee, F. R., Pelham, W. E., Bukstein, O. G., Daviss, W. B., McDermott, M. P. & the CAT study team. (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. Journal of the American Academy of Child & Adolescent Psychiatry, 47, 180-188.
58. Pliszka, S. & AACAP Work Group on Quality Issues. (2007). Practice arameters for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894-921.
59. Popper, C. W. (1995). Combining methylphenidate and clonidine: pharmacological questions and news reports about sudden death. Journal of Child and Adolescent Psychopharmacology, 5, 157-166.
60. Popper, C. W. (2000). Pharmacologic alternatives to psychostimulants for he treatment of attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 605-646.
61. Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polsner, D. A. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 10, 193-204.
62. Richardson, A. J. & Puri, B. K. (2002). A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 233-239.
63. Richardson, A. J. & Montgomery, P. (2005). The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics, 115, 1360-1366.
64. Schlack, R., Hölling, H., Kurth, B. M. & Huss, M. (2007). Die Prävalenz der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern und Jugendlichen in Deutschland. BGB, 50, 827-835.
65. Sobanski, E. & Alm, B. (2004). Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) im Erwachsenenalter. Nervenarzt, 75, 697-716.
66. Solhkhah, R., Wilens, T. E., Daly, J., Prince, J. B., Van Patten, S. L. & Biederman, J. (2005). Bupropion SR For the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. Journal of Child and Adolescent Psychopharmacology, 15, 777-786. (Pubitemid 41567149)
67. Spencer, T. & Biederman, J. (2002). Non-stimulant treatment for attention-deficit/hyperactivity disorder. Journal of Attention Disorders, 6, 109-119.
68. Starobrat-Hermelin, B. & Kozielec, T. (1997). The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnesium Research, 10, 149-156.
69. Stevens, L. J., Zentall, S. S., Deck, J. L., Abate, M. L., Watkins, B. A., Lipp, S. R. & Burgess, J. R. (1995). Essential fatty acid metabolism in boys with attention deficit hyperactivity disorder. American Journal of Clinical Nutrition, 62, 761-768.
70. Stevens, L., Zhang, W., Peck, L., Kuczek, T., Grevsted, N., Mahon, A., Zentall, S. S., Arnold, E. & Burgess, J. R. (2003). EFA supplementation in children with attention, hyperactivity, and other disruptive behaviours. Lipids, 38, 1007-1021.
71. Trebaticka, J., Kopasova, S., Hradecna, Z., Cinovsky, K., Skodacek, I., Suba, J., Muchova, J., Zitnanova, I., Waczulikova, I., Rohdewald, P. & Durackova, Z. (2006). Treatment of ADHD with french maritime pine bark extract, Pycnogenol®. European Child and Adolescent Psychiatry, 15, 329-335.
72. Trott, G. E., Menzel, M., Friese, H. J. & Nissen, G. (1991). Wirksamkeit und Verträglichkeit des selektiven MAO-A-Inhibitors Moclobemid bei Kindern mit hyperkinetischem Syndrom. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 19, 248-253.
73. Voigt, R. G., Llorente, A. M., Jensen, C. L., Fraley, J. K., Berretta, M. C. & Heird, W. C. (2001). A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics, 139, 189-196. (Pubitemid 32721703)
74. Vorstand der Bundesärztekammer. (2005). Stellungnahme zur «Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS)». Deutsches Ärzteblatt, 102, 2562-2568.
75. Ward, N. I. (1997). Assessment of chemical factors in relation to child hyperativity. Journal of Nutritional and Environmental Medicine (Abington), 7, 333-342. (Pubitemid 28143479)
76. Werry, J., Aman, M. & Lampen, E. (1976). Haloperidol and methylphenidate in hyperactive children. Acta Paediatrica, 42, 6-40.
77. Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R. & Prince, J. (2001). A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry, 158, 282-288. (Pubitemid 32116526)
78. Wilens, T. E., Prince, J. B., Spencer, T., Van Patten, S. L., Doyle, R., Girard, K., Hammerness, P., Goldman, S., Brown, S. & Biederman, J. (2003). An open trial of bupropion for the treatment of adults with attention-deficit/ hyperactivity disorder and bipolar disorder. Biological Psychiatry, 54, 9-16.
79. Wilens, T. (2006). Mechanism of action of agents used in attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 67 (suppl. 8), 32-37. (Pubitemid 44389276)
80. Wood, J. G., Crager, J. L., Delap, C. M. & Heiskell, K. D. (2007). Beyond Methylphenidate. Nonstimulant medications for youth with ADHD. Journal of Attention Disorders, 11, 341-350.
81. Young, G. S., Maharaj, N. J. & Conquer, J. A. (2004). Blood phospholipids fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids, 39, 117-123.
82. Young, G. & Conquer, J. (2005). Omega-3-fatty acids and neuropsychiatric disorders. Reproduction Nutrition Development, 45, 1-28.